| Filed On | Filing |
|---|---|
| 26 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. |
| 13 Oct 2026 | 10-KT |
| 28 Sep 2026 | NT 10-K |
| 15 Sep 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Effective September 10, 2026, the Board of Directors of the Company approved a change in the Company’s fiscal year end from October 31 to June 30, effective for the fiscal year ending June 30, 2026. |
| 15 Sep 2026 |
8-K: Other Events
Company looks to broaden its Southeast presence to support healthcare providers navigating newly enacted state laws providing for certain stem cell and regenerative medicine therapies. |
| 14 Sep 2026 | NT 10-Q |
| 01 Sep 2026 | 8-K: Other Events |
| 04 Aug 2026 | 8-K: Other Events |
| 24 Jul 2026 | SCHEDULE 13D/A |
| 24 Jul 2026 | SCHEDULE 13D/A |
| 24 Jul 2026 | SCHEDULE 13G/A |
| 24 Jul 2026 | S-8 |
| 21 Jul 2026 | 8-K: Other Events |
| 08 Jul 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 01 Jul 2026 | 8-K: Other Events |
| 16 Jun 2026 | 8-K: Other Events |
| 15 Jun 2026 | 10-Q |
| 12 Jun 2026 |
Form 4: Grey Wendy, 10% owner and 1 other
Granted 1,250,000 Stock Options |
| 12 Jun 2026 |
Form 4: Bothwell Ian T, Director
Granted 1,250,000 Stock Options |
| 12 Jun 2026 |
Form 4: Shapiro George Craig, Director
Granted 1,250,000 Stock Options |
Loading...
